Clinically, SGLT2 inhibitors have been shown to be effective in reducing cardiovascular events and in preventing CKD progression in mild, but also more advanced, diabetic as well as non-diabetic CKD [1,2,67]. Here, SLC5A2 is linked to chronic kidney disease.